Trials / Unknown
UnknownNCT03413852
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 111 (actual)
- Sponsor
- Embo-Flüssigkeiten A.G. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | SQUID non-adhesive liquid embolic agent | AVM embolization using SQUID non-adhesive liquid embolic agent |
Timeline
- Start date
- 2018-05-11
- Primary completion
- 2022-03-01
- Completion
- 2022-08-01
- First posted
- 2018-01-29
- Last updated
- 2021-04-30
Locations
19 sites across 5 countries: Belgium, Denmark, France, Germany, Italy
Source: ClinicalTrials.gov record NCT03413852. Inclusion in this directory is not an endorsement.